Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pipeline Watch: Phase III Starts In Social Anxiety, Alopecia Areata And COVID-19

GSK/Vir's Sotrovimab Approved In US For COVID-19

Executive Summary

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

 

The table above records the past week's changes to the progress of selected potential new products through the clinical trial pipeline, using data from Informa Pharma Intelligence's Biomedtracker. It lists drugs for which an important event was recorded between 21 May and 27 May, divided by event type.

Hyperlinks in the table take subscribers to the relevant event section of Biomedtracker where more details can be found, or to articles on the Scrip website where the results of clinical trials, or details of an approval, are explored and analyzed.

Events can include Phase II and Phase III clinical trial initiations and the release of top-line and updated clinical trial results.

The change to Biomedtracker's Likelihood of Approval (LOA) metric, and the new LOA, are also included as a percentage for products where available. The LOA is based on Biomedtracker's view of the historical progress of drugs developed within a particular disease sector, combined with an opinion of its analysts.

A brief summary of product approvals, and new indications, from around the world are also included. Make use of the tabs, scroll button and search function to see each section.

A companion resource, the Pink Sheet's regulatory-focused FDA Performance Tracker, follows regulatory milestones such as marketing submissions, approvals, user fee dates, and complete response letters.

 

Related Content

Topics

UsernamePublicRestriction

Register

SC144440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel